395 related articles for article (PubMed ID: 27135782)
21. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
[TBL] [Abstract][Full Text] [Related]
22. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
Tokumasu M; Murata C; Shimada A; Ohki K; Hayashi Y; Saito AM; Fujimoto J; Horibe K; Nagao M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Tomizawa D; Taga T; Tawa A; Tanaka S; Heike T; Adachi S
Leukemia; 2015 Dec; 29(12):2438-41. PubMed ID: 25975190
[No Abstract] [Full Text] [Related]
23. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CXCR4 expression in acute myeloid leukemia.
Du W; Lu C; Zhu X; Hu D; Chen X; Li J; Liu W; Zhu J; He Y; Yao J
Cancer Med; 2019 Nov; 8(15):6595-6603. PubMed ID: 31518054
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
26. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
27. CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia.
Mannelli F; Cutini I; Gianfaldoni G; Bencini S; Scappini B; Pancani F; Ponziani V; Bonetti MI; Biagiotti C; Longo G; Bosi A
Cytometry B Clin Cytom; 2014 Sep; 86(5):340-9. PubMed ID: 24500843
[TBL] [Abstract][Full Text] [Related]
28. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
29. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
30. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
31. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
32. [Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].
Park SH; Chi HS; Park SJ; Jang S; Park CJ
Korean J Lab Med; 2010 Jun; 30(3):231-8. PubMed ID: 20603581
[TBL] [Abstract][Full Text] [Related]
33. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
Shafik NF; Ibraheem D; Selim MM; Allam RM; Fathalla LA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e363-e375. PubMed ID: 34972661
[TBL] [Abstract][Full Text] [Related]
37. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination.
Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J
Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815
[TBL] [Abstract][Full Text] [Related]
38. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
39. Relative receptor tyrosine kinases and anti-apoptotic transcripts hold potential for predicting inferior outcome in adult acute myeloid leukemia: a prospective pilot study.
Sharawat SK; Vishnubhatla S; Bakhshi R; Raina V; Kumar L; Sharma A; Bakhshi S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):501-508.e2. PubMed ID: 25065779
[TBL] [Abstract][Full Text] [Related]
40. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
